Morgan Stanley’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Morgan Stanley’s Portfolio PEARW Stock Details PEARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-740	Closed	-$14	–	7817
2023 Q1	$14	Hold	740	–	–	﹤0.01%	7654
2022 Q4	$110	Hold	740	–	–	﹤0.01%	7689
2022 Q3	$0	Hold	740	–	–	﹤0.01%	8036
2022 Q2	$0	Hold	740	–	–	﹤0.01%	8134
2022 Q1	$1K	Hold	740	–	–	﹤0.01%	7909
2021 Q4	$0	Buy	+740	New	+$751	﹤0.01%	8239

Other funds holding PEARW

Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Morgan Stanley's PEARW Position: Q2 2023 in Review

Morgan Stanley sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q2 2023, closing a stake of 740 shares — an estimated $14 sold.

Morgan Stanley first reported a position in PEARW in Q4 2021 and held it in 6 quarters. The position peaked at $1K in Q1 2022. 2 funds tracked by Wall St. Rank hold PEARW as of Q2 2023.

Morgan Stanley reported no remaining Pear Therapeutics, Inc. Warrant position as of Q2 2023 after selling out during the quarter.
Morgan Stanley sold 740 Pear Therapeutics, Inc. Warrant shares in Q2 2023, an estimated $14.
Morgan Stanley first reported a position in Pear Therapeutics, Inc. Warrant in Q4 2021 and held it in 6 quarters.
Morgan Stanley's Pear Therapeutics, Inc. Warrant position peaked at $1K in Q1 2022.
2 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q2 2023.

Based on Morgan Stanley's 13F filing for Q2 2023, filed 14 Aug 2023.